LGALS3 and Huntington disease: A combination of multiple biomarkers, such as plasma Gal3 plus other disease-specific markers (e.g., the level of plasma mHTT for HD), is needed to design reliable biomarker sets to monitor the disease progression of HD and other neurodegenerative diseases.